{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This study was a Phase III, multicenter, randomized, double-blind, controlled study"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This study was a Phase III, multicenter, randomized, double-blind, controlled study conducted from 2011 to 2019"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult patients with ARCO Stage I and II ONFH were randomized"
      },
      "Intervention": {
        "score": 2,
        "evidence": "core decompression with osteoblastic cell transplantation (5 mL with 20 x 10 6 cells/mL in the study group) or core decompression with placebo (5 mL of solution without cells in the control group)"
      },
      "Objective": {
        "score": 1,
        "evidence": "Is core decompression combined with autologous osteoblastic cell transplantation superior to core decompression with placebo implantation in relieving disease-associated pain and preventing radiologic ONFH progression in patients with nontraumatic early-stage ONFH?"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary efficacy endpoint was the composite treatment response at 24 months"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "patients with ARCO Stage I and II ONFH were randomized (1:1)"
      },
      "Blinding": {
        "score": 3,
        "evidence": "double-blind"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Thirty percent (68 of 230) of the screened patients were eligible for inclusion in the study"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Forty-nine patients were included in the efficacy analyses"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "There was no difference between the study and control groups in the proportion of patients who achieved a composite treatment response at 24 months (61% [14 of 23] versus 69% [18 of 26]; p = 0.54)"
      },
      "Harms": {
        "score": 1,
        "evidence": "There were no serious adverse events related to the study treatment"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrails.gov registry number: NCT01529008"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 23,
    "max_score": 25
  },
  "model": "gpt-4o"
}